Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 1, 2011

CSL Negotiates Option to Pevion’s Candida Vaccine for Australia and New Zealand

  • Australian biotech firm CSL negotiated an option to license Pevion Biotech’s early clinical-stage therapeutic Candida vaccine for commercialization in Australia and New Zealand. The virosome-based vaccine is in development for the treatment of recurrent vulvovaginal candidiasis (chronic recurrent thrush). The firms in addition signed a long-term supply agreement under which CSL will manufacture specific biolgocial components used by Pevion in the in vitro assembly process for its virus-like particle virosome technology, which form the basis of the latter’s in-house and partnered pipeline products.

    Swiss firm Pevion’s virosome technology is a carrier and adjuvant system designed specifically for subunit vaccines, and has already been used for development of the marketed vaccines Epaxal® and Inflexal® V (both marketed by Crucell). The firm’s most advanced product, a virosome-based malaria vaccine candidate PEV3, has been outlicensed to Mymetics and is in late-stage clinical development. Mymetics also holds a license to a Phase I-stage HIV vaccine program.

    Pevion’s remaining in-house pipeline is headed by PEV7, which is being developed both for intramuscular delivery and intravaginal delivery for treating recurrent thrush. The firm reported postive data from an ongoing Phase I clinical trial back in November 2010. Pevion’s development programs in addition include a respiratory syncytial virus candidate, PEV4, which is in late-stage preclinical development, and an early clinical-stage HER2-targeting breast cancer candidate, PEV6, has been licensed out to BioLife Science. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »